Ann: Shareholder Update , page-16

BioE: IMO if and when a current pharma partner extends the relationship substantially, it will be a trigger for VC funds.

To my knowledge the Pfiz animal trials are definitely still running. They were extended due to factors out of the control of either party. Both relationships Pfiz and Janss seem to be close.

And it's worth mentioning, any info I receive from Mgmt, I cross check with major shareholders.

My earlier post was concerning your lack of rant concerning PYC evolving the discovery platform to optimise the screening of the libraries to identify cell-specific peptides that can penetrate cell membranes.
SoT